Tag : Study

CCT Impact

Cannabis Study Reveals Optimal Canopy Density for Highest Yield, Efficiency and Profitability in Greenhouse Growing Environment

CCT IMPACT Agent
Phylos® alongside its research and cultivation partner, Progressive Plant Research (PPR) have announced the results of their day-neutral cannabis density trial. The purpose of this study was to establish the effect of plant density on biomass, extraction yield, cannabinoids, terpenes, and other traits. Findings from this study highlight how optimizing density treatments can improve......
CCT Impact

Labstat International Inc. & The Blinc Group Study Finds Vape Habits Don’t Cross Borders

CCT IMPACT Agent
Labstat International Inc., Canada’s leading independent third-party cannabis testing company, in partnership with The Blinc Group, Inc., the regulatory-focused designer and provider of premium, customized and bespoke vaporizer technologies, have conducted the first North American Cannabis Vape Consumption Survey aimed at better understanding how consumers use vaping devices. The study, Cannabis Puffing......
CCT Impact

Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb’s Anti-PD-1 Opdivo®

CCT IMPACT Agent
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that the Israeli Ministry of Health (MoH) cleared the company to proceed with its Proof-of-Concept (POC), Phase I clinical trial of Biomica’s drug candidate BMC-128 in patients with Non-Small......
CCT Impact

Cannformatics Announces Publication of Groundbreaking Study Identifying Cannabis-Responsive™ Biomarkers in Children with Autism Spectrum Disorder

CCT IMPACT Agent
Cannformatics, an early-stage biotechnology startup focused on personalizing medical cannabis treatment through the identification and application of saliva-based Cannabis-Responsive biomarkers, announced today that the journal Cannabis and Cannabinoid Research has published results from its observational pilot study of children with ASD. Participants in the study were racially, ethnically, and socio-economically diverse boys and girls......
CCT Impact

CBD Oracle Lab Study Shows Some Delta-8 THC Products Reach 7700% of the Legal Delta-9 THC Limit

CCT IMPACT Agent
Three-quarters of delta-8 THC products sold in the US are in violation of federal law, a new lab analysis has revealed. The report, commissioned by CBD Oracle and conducted by FESA Labs, analyzed the delta-8 and delta-9 THC content of 51 of the most popular hemp-derived delta-8 THC products, finding that 76%......
CCT Impact

Khiron presents its first research study with 1,400 patients

CCT IMPACT Agent
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe, is pleased to announce that the Company presented results from its first research study including 1,453 patients from Khiron-owned Zerenia Clinics at the 29th International Pain Conference in Barranquilla, Colombia,......
CCT Impact

Goodness Growth Holdings™ Subsidiary Resurgent Biosciences Launches First IRB-Approved Research Study on Entheogens & Psychedelic Experiences

CCT IMPACT Agent
Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences, Inc. (“Resurgent”), is actively recruiting 100 participants to take part in an anonymous online survey to research the varying effects of entheogen and psychedelic......
CCT Impact

Chemistree Investee ImmunoFlex™ Completes Clinical Study and Submits US and International Patent Applications

CCT IMPACT Agent
Chemistree Technology Inc. (CSE: CHM) (CSE: CHM.WT) (OTCQB: CHMJF) (the “Company” or “Chemistree”) is pleased to confirm that investee company ImmunoFlex Therapeutics Inc. (“ImmunoFlex”™), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. The exploratory trial was the latest of several small trials where......
CCT Impact

Study: Azuca TiME INFUSION™ Helps Reduce Waste, Save Money & Improve Efficiencies in Edibles Manufacturing

CCT IMPACT Agent
Azuca, the leading all-natural, fast-acting cannabis edibles ingredient brand, today released its new white paper, Stability and Waste Solutions for Edibles Manufacturers. The study reveals that Azuca’s proprietary technology, TiME INFUSION™, not only offers solutions for fast onset and offset consumption, but also helps manufacturers by improving production cost and efficiency by......
CCT Impact

ArthroCBD Shares Study’s Findings for Arthritis Awareness Month

CCT IMPACT Agent
Arthritis is one of the most widespread health conditions in the United States and affects one in four adults, according to the CDC. That’s over 54 million men and women. There are common misconceptions around Arthritis, including what it’s like to live with it. ArthroCBD recently performed quantitative and qualitative studies to “debunk” these......